Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Total Non-Current Liabilities (2016 - 2025)

Ultragenyx Pharmaceutical (RARE) has disclosed Total Non-Current Liabilities for 10 consecutive years, with $458.0 million as the latest value for Q4 2025.

  • Quarterly Total Non-Current Liabilities fell 62.58% to $458.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $458.0 million through Dec 2025, down 62.58% year-over-year, with the annual reading at $458.0 million for FY2025, 62.58% down from the prior year.
  • Total Non-Current Liabilities for Q4 2025 was $458.0 million at Ultragenyx Pharmaceutical, down from $1.2 billion in the prior quarter.
  • The five-year high for Total Non-Current Liabilities was $1.2 billion in Q4 2024, with the low at $196.2 million in Q2 2021.
  • Average Total Non-Current Liabilities over 5 years is $583.5 million, with a median of $412.3 million recorded in 2025.
  • Peak annual rise in Total Non-Current Liabilities hit 253.6% in 2024, while the deepest fall reached 72.43% in 2024.
  • Over 5 years, Total Non-Current Liabilities stood at $598.8 million in 2021, then crashed by 46.98% to $317.5 million in 2022, then rose by 11.26% to $353.3 million in 2023, then soared by 246.47% to $1.2 billion in 2024, then plummeted by 62.58% to $458.0 million in 2025.
  • According to Business Quant data, Total Non-Current Liabilities over the past three periods came in at $458.0 million, $1.2 billion, and $1.1 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.